Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.47 |
| ▸ | SCD | O00767 | 4/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753454 | 0.88 | MGLL (0.49) | MGLLSCDPTGDR2POLBALDH1A1 | |
| SCHEMBL4011732 | 0.86 | MGLL (0.47) | MGLLSCDPTGDR2POLBALDH1A1 | |
| SCHEMBL4012419 | 0.85 | PTGDR2 (0.45) | MGLLSCDPTGDR2POLBALDH1A1 | |
| SCHEMBL7844206 | 0.85 | MGLL (0.47) | MGLLSCDPTGDR2POLBALDH1A1 | |
| SCHEMBL13054802 | 0.85 | PTGDR2 (0.44) | MGLLSCDPTGDR2POLBALDH1A1 | |
| SCHEMBL3759889 | 0.84 | NAMPT (0.48) | MGLLSCDPTGDR2POLBALDH1A1 | |
| SCHEMBL3759916 | 0.84 | MALT1 (0.42) | ALDH1A1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15710402 | 0.83 | MGLL (0.45) | MGLLSCDPTGDR2POLBALDH1A1 | |
| SCHEMBL7830249 | 0.82 | MGLL (0.52) | MGLLSCDPTGDR2POLBALDH1A1 | |
| SCHEMBL13054799 | 0.82 | MGLL (0.44) | MGLLSCDPTGDR2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298384-A1 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-11-25 | — | — | US | disclosed |
| WO-2008143649-A2 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-11-27 | — | — | WO | disclosed |
| CN-1075073-C | Hetero-aromatic ring substituted phenyloxazolidinone antimicrobials | UPJOHN CO (US) | 2001-11-21 | — | — | CN | disclosed |
| EP-0807112-B1 | HETERO-AROMATIC RING SUBSTITUTED PHENYLOXAZOLIDINONE ANTIMICROBIALS | UPJOHN CO (US) | 2001-09-05 | — | — | EP | disclosed |
| US-6124334-A | A BACTERICIDE TREATING INFECTIONS CAUSED BY GRAM-POSITIVE AEROBIC BACTERIA SUCH AS STAPHYLOCOCCUS, STREPTOCOCCUS AND ENTEROCOCCUS AS WELL AS ANAEROBIC ORGANISMS SUCH AS BACTEROIDES AND CLOSTRIDIUM AND MYCOBACTERIDIUM | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| US-5910504-A | BACTERICIDES TREATING INFECTIONS | PHARMACIA & UPJOHN (US) | 1999-06-08 | — | — | US | disclosed |
| CN-1172484-A | Phenyl oxazolidinone antibacterial agents substituted with heteroaromatic rings | UPJOHN CO (US) | 1998-02-04 | — | — | CN | disclosed |
| EP-0807112-A1 | HETERO-AROMATIC RING SUBSTITUTED PHENYLOXAZOLIDINONE ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1997-11-19 | — | — | EP | disclosed |
| WO-1996023788-A1 | HETERO-AROMATIC RING SUBSTITUTED PHENYLOXAZOLIDINONE ANTIMICROBIALS | PHARMACIA + UPJOHN COMPANY (US) | 1996-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298384-A1 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | OXA1L, MIF, VIP | MGLL 1065/4885SCD 2708/4885PTGDR2 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.